This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Growth hormone treatment and fat redistribution in children born small for gestational age.
OBJECTIVE To determine whether in children born small for gestational age ( SGA ) high-dose growth hormone ( GH ) treatment is not only associated with catch-up of growth and with gain of lean mass , but also with a more central fat distribution . STUDY DESIGN Short children who were SGA ( n = 25 ; age [ mean + /- SD ] , 5.3 + /- 1.5 years ) were r and omly assigned to remain untreated ( n = 14 ) or to receive GH ( n = 11 ; sc 66 mug/Kg/d ) . Growth status and body composition were assessed at the study 's start , after 1 year , and after 2 years with anthropometry and absorptiometry . RESULTS Children who were treated with GH gained more height and weight than children who were untreated and developed a less adipose body composition ( all P < .0001 ) , as expected . However , these changes were also accompanied by a relatively more centripetal distribution of fat mass ( 0 - 2 year change in ratio of trunk fat to limb fat ; 0.26 + /- 0.23 versus 0.02 + /- 0.15 ; P < .0001 ) . CONCLUSION In children who are SGA , catch-up growth induced by exogenous GH in high doses is accompanied by a less adipose body composition and a more central fat distribution
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .